Fig. 4: Clinical outcomes after matched unrelated donor peripheral blood stem cell transplantation (MUD-PBSCT). | Bone Marrow Transplantation

Fig. 4: Clinical outcomes after matched unrelated donor peripheral blood stem cell transplantation (MUD-PBSCT).

From: Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation

Fig. 4

a The 1-year probability of relapse and nonrelapse mortality (NRM). b The 1-year probability of GvHD-free, relapse-free survival (GRFS), relapse-free survival (RFS), and overall survival (OS).

Back to article page